US panel rejects River Plate, Alcon dry eye drug
SILVER SPRING, Md., June 26 |
SILVER SPRING, Md., June 26 (Reuters) - River Plate Biotechnology did not provide adequate evidence of safety and effectiveness for a proposed drug to treat dry eye, a U.S. advisory panel ruled on Friday.
The committee voted 6-1 against the drug, called Rejena. Alcon Inc ACL.N holds U.S. marketing rights for the product.
(Reporting by Lisa Richwine)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters